Hot off the Press June 2024

We have collated some great articles and material published over the last month. Click on the links below to read the  abstract or download the full paper.


The lymphedema patient experience within the healthcare system: a cross-sectional epidemiologic assessment

Catharine Bowman, Stanley G. Rockson. Sci Rep. 2024

Download full paper

Breast Cancer-Related Lymphedema Assessed via Tissue Dielectric Constant Measurements

Carel Toro, Biura Markarian, Harvey N. Mayrovitz. Cureus. 2024 Apr 29.

Download full paper

Hit by the wave: The experiences of adult males living with lymphoedema

Josianne Scerri, Sarah Cilia Vincenti, Michael Galea, Carmel Cefai, Paulann Grech, Alexei Sammut, Christie Attard. PLoS One. 2024 May 31

Download full paper

Development and psychometric testing of the lymphedema self-management support scale for breast cancer survivors

Xin Fu, Aomei Shen, Lichuan Zhang, Yujie Wang, Qian Lu, Asia Pac J Oncol Nurs. 2024 Apr 22. Jun

Download full paper

Management Strategies

Management of lymphedema is really a matter in patients with breast cancer

Jung Eun Choi, Min Cheol Chang. World J Clin Cases. 2024 May 26.-2486.

Download full paper

Surgical treatment algorithm for breast cancer lymphedema-a systematic review

Caroline Lilja, Christoffer Bing Madsen, Tine Engberg Damsgaard, Jens Ahm Sørensen, Jørn Bo Thomsen. Gland Surg. 2024 May 27

Download full paper

Treatment of Lymphedema in Patients With Advanced Cancer Receiving Palliative Care: A Single-Center Experience

Keisuke Shimbo, Haruka Kawamoto, Isao Koshima. Eplasty. 2024 May 9

Download full paper

Lymphovenous Anastomosis for the External and Internal Types of Head and Neck Lymphedema: A Case Series and Preliminary Clinical Results

Ying-Sheng Lin, Chia-Ju Liu, Chen-Han Chou. Plast Reconstr Surg Glob Open. 2024 Jun 5. Jun

Download full paper

Reducing the burden: managing lymphoedema and its complications - click for abstract

Reducing the burden: managing lymphoedema and its complications

Drew Payne, Br J Community Nurs. 2024 Jun 2.

Lymphoedema effects approximately 200 000 people in UK. It is a chronic condition without a cure but there is much that can be done to ease and manage these complications. This article looks at the eight most common complications, providing advise on how to manage them, derived from the literature and the author’s own experience. It also presents advise on how nurses can promote self-management of these complications, promoting patients’ self-care.:10.12968.29.6.296

Patients and methods: The efficacy of LVA for unilateral arm lymphedema was evaluated using BIA in a retrospective cohort. Limb circumference and arm body water volume (ABW) of the affected and unaffected arms were measured before and after LVA. Mean water volume reduction (ΔABW) and edema reduction rate by arm LVA were compared with values for leg LVA cited from our previous report as a historical control.

Results: Nineteen consecutive patients were enrolled. The mean ΔABW and edema reduction rate by BIA were 0.267 L and 46.0%, respectively. The decreasing rate of ABW by BIA was significantly larger than those of the upper extremity lymphedema index and sum of 5 circumferences measurement methods. ΔABW could be predicted by a regression line based on the preoperative water volume difference between affected and unaffected limbs. The mean edema reduction rates for arm and leg LVA were comparable.

Conclusion: The water reductive effect of LVA on upper-limb lymphedema was demonstrated by BIA assessment. BIA can reflect the effect of LVA more sensitively than conventional objective measurements and may facilitate the interpretation of LVA results. Although water volume reduction by arm LVA was less than that by leg LVA, the edema reduction rates were comparable.

New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial - click for abstract

New Strategy for Breast Cancer Related Lymphedema Treatment by Endermology: ELOCS Phase II Randomized Controlled Trial

Julie Malloizel-Delaunay, Ariane Weyl, Clara Brusq, Benoît Chaput, Barbara Garmy-Susini, Vanina Bongard, Charlotte Vaysse. Clin Breast Cancer. 2024 May 2.

BACKGROUND: This phase II trial sought to be the first of its kind to estimate the success rate of endermology in reducing breast cancer-related lymphedema.
PATIENTS AND METHODS: ELOCS is a French, monocentric, randomized, open-label phase II trial. Patients were randomized to receive the following over a 5-day treatment period: standard intensive decongestant treatment (IDT) (bandages and manual lymphatic drainage MLD) (group 1); IDT including bandages, MLD, and Cellu M6 (group 2); and IDT including bandages and Cellu M6 (Group 3). The main endpoint was the success rate in each group, (reduction of at least 30% in the excess volume). We estimated that endermology treatment (groups 2 and 3) would be of interest successes occurred in at least 21 out of 31 patients.
RESULTS: A total of 93 patients were included (31 patients in each of the 3 groups). The median age was 64.5 years (IQR: [56.4-71.3]). Patients were treated with mastectomy (n = 35), axillary lymphadenectomy (n = 80), radiotherapy (n = 91), and chemotherapy (n = 68). The mean relative reduction in excess volume was 38% in group 1, 33% in group 2, and 34% in group 3. Success rate was 58.1% in group 1 (18/31, P = ,0237), 51.6% (16/31, P = ,5) in group 2, and 64.5% (20/31, P = ,075) in group 3. In the LPG groups (2 and 3), 10/62 (16%) patients found LPG painful and 9/62 (15%) patients considered it to be unpleasant.
CONCLUSION: Even though the critical threshold of 21 successes was not met, this study was the first to validate a standardized and reproducible endermology protocol.:10.1016/j.clbc.2024.05.009